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Abstract
Background:  General practitioners' (GPs) negative beliefs about nicotine dependence
medications may act as barriers to prescribing them.
Methods: Study1: Twenty-five GPs from 16 practices across London were interviewed in this
qualitative study. Framework analysis was used to identify key themes. Study 2: A convenience
sample of 367 GPs completed an internet-based survey. Path-analysis was used to examine the
relations between beliefs and intentions to prescribe smoking cessation medications.
Results: Study 1: Whilst nicotine replacement therapy (NRT) and bupropion were generally
perceived as effective and cost-effective, the effectiveness of NRT was seen as critically dependent
on behavioural support for smoking cessation. This dependence appeared to be influenced by
perceptions that without support smokers would neglect psychological aspects of smoking and use
NRT incorrectly. GPs perceived bupropion as dangerous and were concerned about its side-
effects. Study 2: GPs' beliefs had medium (NRT, f2 = .23) to large (bupropion, f2=.45; NRT without
support, f2=.59) effects on their intentions to prescribe medications. Beliefs about effectiveness of
NRT and bupropion and the perceived danger of bupropion were the key predictors of intentions
to prescribe NRT and bupropion, respectively. Beliefs about neglecting psychological aspects of
smoking and incorrect use had indirect effects on intentions to prescribe NRT without support,
operating via beliefs about effectiveness.
Conclusion: GPs vary in their beliefs about the effectiveness and safety of smoking cessation
medications. Their intentions to prescribe these medications vary in line with these beliefs.
Interventions aimed at increasing the likelihood with which GPs prescribe these medications may
be more effective if they addressed these beliefs.
Background
Helping people to stop smoking is one of the most effec-
tive ways of preventing premature death and reducing
health inequalities [1]. In the UK, a main strategy to
achieve this is to increase the number of smokers that use
the NHS Stop Smoking Services (NHS-SSS) which offer
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free individual or group support by full-time staff trained
in providing behavioural support and nicotine depend-
ence medications, nicotine replacement therapy (NRT)
and bupropion (Zyban), on prescription [1]. These medi-
cations are available on prescription to all smokers who
want to stop independent of their desire to use NHS-
SSS[2]. The medications and services, alone and in combi-
nation, are highly cost-effective in comparison to the great
majority of medical interventions [2,3].
NRT provides a means of delivering nicotine that was for-
merly acquired through smoking, and thereby relieves
cravings for nicotine and the symptoms of nicotine with-
drawal. Meta-analyses show that quitting with NRT has an
odds ratio of 1.7 compared to quitting with placebo or no
treatment one year after the intervention [4]. Even when
NRT is used without support (e.g. bought over the coun-
ter), its benefit is undiminished [5]. In addition to being
effective, NRT is considered safe, although some negative
effects of nicotine on myocardial workload mean that
guidelines recommend that patients with cardiovascular
conditions only use NRT after careful consideration. The
effect of nicotine acquired through NRT is, however, no
worse than that acquired through smoking [4].
Apart from NRT, the NHS also supports the use of bupro-
pion as an aid for smokers who want to stop smoking. The
exact mechanisms by which it facilitates smoking cessa-
tion are unknown although it is assumed to work directly
on the brain pathways involved in addiction and with-
drawal [4]. Meta-analyses show that quitting with bupro-
pion has an odds ratio of 2.4 compared to quitting with
placebo one year after the intervention [4]. Bupropion
increases the risk of epileptic seizures, and is therefore
contraindicated in patients who are at risk for seizures.
Seizures occur in about 1 in 1000 patients using bupro-
pion. This relative risk is only an approximate estimate
because no direct comparative studies have been con-
ducted. A recent case-series analysis concludes that despite
statistically non-significant findings there is probably an
increased risk of seizures associated with the use of bupro-
pion, with a relative incidence of seizures of 3.62 (95% CI
0.87 to 15.09) [6].
Smoking cessation guidelines [2] and the new NICE Pub-
lic Health Intervention Guidance [7] recommend that
general practitioners (GPs) advise all smokers to stop
smoking and provide medications and/or refer smokers
who are motivated to NHS-SSS. The guidance recom-
mends that GPs offer the behavioural support (e.g. NHS-
SSS) first. If smokers are not interested they should be
offered prescriptions for NRT or bupropion [7]. It is esti-
mated, however, that smoking cessation advice is given in
only 20%–30% of UK primary care consultations with
smokers [8]. One study estimated that only 6% of GPs
have referred smokers to smokers' clinics and 41% to
nurses trained in smoking cessation in the previous
month [9]. Another study showed that less than 5% of
smokers were advised about NRT by their GP [10]. Study-
ing GP self-reports, 80% of patient requests for NRT and
59% of patient requests for bupropion were found to be
honoured by GPs [11].
Failure to implement evidence-based guidelines is not
restricted to smoking cessation [12,13]. Interventions to
increase adherence to guidelines using a wide-variety of
methods including incentives, prompts/reminders, and
education have had mixed results and there is no clear evi-
dence to favour any particular strategy [13]. Critiques of
this large literature highlight that most interventions lack
explicit rationales or theoretical bases [12,14]. A first step
to developing an intervention to increase the frequency
with which GPs prescribe smoking cessation medications
to smokers who are motivated is to identify the factors
that may influence this clinical practice. Motivational the-
ories propose that motivation is a proximal determinant
of behaviour [15-18]. Interventions should therefore tar-
get factors that determine motivation. Examples of such
determinants include beliefs about the consequences of a
behaviour and attitudes towards performing the behav-
iour.
A systematic review showed that while the majority of GPs
and family physicians do not hold negative beliefs and
attitudes towards discussing smoking cessation with their
patients, a sizeable minority do [19]. Discussing smoking
cessation was perceived as too time consuming by 42%.
Thirty-eight percent believed it was ineffective and 22%
reported lacking confidence in their ability to discuss
smoking cessation with their patients. Few studies, how-
ever, have assessed beliefs about smoking cessation med-
ications. Those that have, report that about 20% of GPs
believed that assisting smokers by directing them to use
NRT is inappropriate, unfeasible, and not cost-effective
[9,20]. Fewer believe it is ineffective [9,20] and 30%
would give NRT a low priority in the drug budget [11].
Many GPs are concerned about the side-effects of bupro-
pion (69%) and a third would give bupropion a low pri-
ority in the drug budget [11]. In general, little is known
about GPs perceptions of smoking cessation medications.
In particular, the quantitative nature of the available evi-
dence limits the insight they can provide to fully under-
stand GPs' perceptions about them. For example, whilst
this research showed that sizable proportions of GPs
believed that assisting smokers with NRT was inappropri-
ate [20], it is unknown why GPs believed this. Similarly, it
is unclear why around 30% of GPs would give NRT and
bupropion a low priority in the drug budget [11].
Although the proportions of GPs who believe that NRT is
ineffective amounts to only around one-tenth [9,20], thisBMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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finding is surprising given the clear evidence of the effec-
tiveness of NRT [4]. Identifying the specific beliefs that
underlie some of the broad categories of beliefs is impor-
tant in designing interventions to change GPs' beliefs.
A major feature of qualitative methods is their ability to
describe and display phenomena as experienced by the
study population in fine detail and in the study partici-
pants' own terms. They therefore offer the opportunity to
'unpack' phenomena, to see what they are about or what
lies behind them [21]. Qualitative research also allows
associations that occur in people's thinking or acting to be
identified [21]. The aim of Study 1 is to provide an in-
depth understanding of the basis for GPs' beliefs about
smoking cessation medication, using qualitative meth-
ods. This is followed by a second study aimed at describ-
ing the prevalence of these beliefs and the strength of their
association with intentions to recommend smoking cessa-
tion medications.
Methods
Study 1
Participants
Twenty-five GPs, whose practices are part of the Medical
Research Council General Practice Research Framework
(MRC GPRF), were interviewed. Ten of the GPs were
female and fifteen were male (age range 27 to 60).
The interview
Interviews were conducted by a researcher trained in qual-
itative interview techniques (FV). A semi-structured inter-
view schedule was used covering topics related to
discussing smoking with smokers, NRT, bupropion, and
behavioural support for smoking cessation (NHS clinics
and local services). Emphasis was given to criteria used for
deciding whether or not treatments are introduced into
health care [22], that is, their effectiveness and cost-effec-
tiveness. The interview schedule was piloted with three
GPs from a London general practice, and refined where
appropriate. Interviews were audio-taped and transcribed
verbatim.
Data Analysis
The data were managed using NVivo software for qualita-
tive data analysis and analysed using the framework
method [21]. Framework analysis has five stages: familiar-
isation, identifying a thematic framework, indexing,
charting, mapping and interpretation. Details of the anal-
ysis process are shown in Table 1. Internal validity was
established through the 'constant comparative method'
[23], involving constant and repeated checking of the
interpretation of the data, inherent in the five stages of
framework analysis [21]. In addition, the thematic analy-
sis was supported and verified by two experienced
researchers by ascertaining consensus in the interpreta-
tion. The internal validity was enhanced by displaying
quotations to supplement the analysis where quotations
explicitly document linkages or explanations. To address
external validity, 'methods triangulation' [21], which
relies on generating data by another method, was used.
Study 2 serves for triangulation and validation of the
themes that emerged from Study 1. Only themes regard-
ing smoking cessation medications are shown in the
results section. Themes relating to smoking cessation serv-
ices are presented elsewhere [24].
Procedure
The MRC GPRF sent invitation letters to all 128 practices
in the framework in the Greater London area. Of these, 16
agreed to take part in the study. From these, 30 GPs agreed
to be interviewed. Five did not have time to be inter-
viewed in the limited data collection phase of the study.
GPs were interviewed in their practices. At the start of the
interview they were assured of anonymity. The interviews
lasted between 10 and 30 minutes, depending on how
much each participant had to say. After the interviews, all
participants were offered £20 book tokens as compensa-
tion for their time.
Table 1: Process of data analysis
FV reads interview transcripts and generates codes for beliefs reported by GPs about intervening with smokers and about smoking cessation 
medications and services.
FV reads and compares the codes to identify themes within these: the principal beliefs GPs reported about intervening with smokers and about 
smoking cessation medications and services.
Data relating to each theme are assembled. FV, SH, and TM independently read these and discuss definitions of themes and the data within these. 
During this process some definitions are altered and some data re-coded.
FV re-codes all transcripts for these themes.
FV begins coding for sub-themes within themes: more detailed variations in GPs' thinking within themes. Sub-themes include GPs' explanations for 
reasons behind preferring practices to smoking cessation clinics.
The process of coding for sub-themes includes building a framework containing themes and sub-themes. This process includes shifting themes to 
sub-themes and vice versa.
The framework is arranged in tables using text segments to represent the themes in order to facilitate understanding of the data
FV, SH, and TM study the tables to gain an understanding of themes and sub-themes and decide on main issues. Disagreements are discussed and 
amendments made where appropriate.BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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Study 2
Participants
Three-hundred and sixty-seven general practitioners com-
pleted the survey. All were users of an internet-based med-
ical information service provider. At the time of study,
4743 UK GPs (~12% of UK GPs) were registered users of
this information services provider. Of the 381 GPs who
were invited to participate, only fourteen (4%) did not
complete the questionnaire. Seven (2%) declined and
seven (2%) deferred completion. Respondents were gen-
erally representative of the general population of GPs
based on the Department of Health Statistics for General
Medical Practitioners with a bias towards men responding
(about 60% of GPs in the UK are male) (Table 2). This
bias reflects the profile of GPs that are registered with the
service provider.
Procedure
A questionnaire was presented to any member of the serv-
ice provider registered as a general practitioner upon
accessing the service during four days in November 2004.
When members log on to visit the Web site, they must give
their General Medical Council number. Software checks
this information as well as a list of available question-
naires. Members then have three choices: (i) complete the
questionnaire immediately, (ii) defer completion to
another time, or (iii) refuse completion. The service pro-
vider carries out regular profit and not-for-profit survey
research among its members and has been successfully
used for academic purposes [25]. Rewards are offered to
GPs if they respond to questionnaires on a regular basis.
Measures
The questionnaire content was designed on the basis of
the interviews with the 25 GPs as reported in Study 1. It
was piloted with 22 GPs using the same methods as the
main study.
Intention
Intention is defined as the expressed motivation to per-
form some behaviour or achieve some goal [26]. Two
items were used to measure intentions using the stem,
"Thinking about the next month, do you intend to..." and
"Thinking about the next month, how likely is it that you
will...". The stems were followed by "...prescribe NRT to
all motivated smokers" (α = .756), "...prescribe bupro-
pion to all motivated smokers" (α = .866). Only one item
was used to measure intentions to prescribe NRT without
behavioural support due to space restrictions on the ques-
tionnaire, using the "...intend to..." stem with "...prescribe
NRT to all motivated smokers even without behavioural
support". The "...intend to..." stem had a response range
from 1 (definitely do not) to 7 (definitely do). The "...how
likely..." stem had a response range from 1 (very unlikely)
to 7 (very likely).
Beliefs
Perceived effectiveness was measured using the stem "...is
effective at helping motivated smokers to stop smoking"
and perceived cost-effectiveness using the stem "...is effec-
tive enough to justify its cost" [9]. Both perceived effec-
tiveness, and perceived cost-effectiveness were preceded
by "NRT...", and "Bupropion...". Perceived effectiveness of
NRT without behavioural support was measured with the
item "NRT without behavioural support is ineffective at
helping motivated smokers to stop smoking". Perceived
incorrect use and perceived neglect of psychological
aspects of smoking were measured regarding NRT without
behavioural support using the items "NRT without behav-
ioural support will result in NRT being used incorrectly"
and "NRT without behavioural support neglects psycho-
logical aspects of smoking". Concerns about the side-
effects of bupropion was measured with the item "I am
concerned about the side effects of bupropion" based on
a similar measure used in another study [11]. Perceived
danger of bupropion was measured using two items
"Bupropion is dangerous for my patients" and "Bupro-
pion unnecessarily endangers the lives of what for the
most part, are healthy smokers" (α = .821). All beliefs
were measured using a response range from 1 (strongly
disagree) to 7 (strongly agree).
Table 2: Demographic and background details of participants
Characteristic Levels N %
Gender Female 60 16.3%
Male 307 83.7%
Decade of qualification 1960s 11 3%
1970s 122 33.2%
1980s 146 39.8%
1990s 86 23.4%
2000s 2 0.5%
Commitment Full time 323 88%
Pat time 44 12%
Country of training UK 327 89.1%
Other 40 10.9%
Geographical location London 32 8.7%
South East 63 17.2%
South West 40 10.9%
West Midlands 41 11.2%
Eastern 46 12.5%
Trent 44 12%
North West 56 15.3%
Northern and Yorkshire 45 12.3%
Presence of trained practice nurse No 89 24.3%
Yes 277 75.5%
missing 1 0.3%BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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Path analysis
Path analysis is a concise way to organise causal thinking
and is an extension of the statistical method of multiple
linear regression [27]. In addition to multiple regression
analysis, path analysis assembles the antecedents of the
outcome variable into a structure of presumed causal rela-
tionships. Given such a presupposed causal model, path
analysis estimates the magnitude of the linkages between
the variables. The language of the method invokes causal-
ity in speaking of "causal" paths and effects but this lan-
guage assumes that the model is correct [27]. Causal
pathways operating via two or more variables indicate
indirect effects. Indirect effects are very similar to medi-
ated effects. A mediator is a variable "to the extent that it
accounts for the relation between the predictor and the crite-
rion" [28, p. 1176]. To establish the significance of indirect
effects operating through two or more variables covari-
ance structure software is considered superior [29]. The
covariance structure software AMOS [30] was used to cal-
culate the estimate path coefficients using a bootstrapping
method (2000 bootstrap samples were used) [31]. The
path models were based on Study 1. All beliefs were ini-
tially considered as direct predictors of intentions (non
significant paths were removed from the models). The
Squared Multiple Correlation (SMC) of each outcome var-
iable was calculated. The SMC is the equivalent to an R-
squared (R2) in linear regression [32]. Effect sizes were cal-
culated for the variance explained in intentions using f2 =
R2/(1-R2) [33]. According to Cohen an f2 value of 0.02 is
small, an f2 value of 0.15 is medium, and an f2 value of
0.35 is large.
Data preparation
Prior to analysis, the variables were examined for accuracy
of data entry, missing values, and violations of multivari-
ate assumptions and passed all required tests (some vari-
ables were not normally distributed but bootstrapping is
unaffected by this). There were few missing data, well
below 5% in all instances. Missing values were replaced
with the mean responses of the variable.
Results
Study 1
Nicotine Replacement Therapy
GPs acknowledged that NRT had a positive impact on
smokers' chances of stopping smoking even though most
smokers would fail with NRT. Beliefs that contributed to
this perception included the belief that NRT would help
with the physical addiction to nicotine and in particular
with nicotine cravings. In particular forms, such as deliv-
ered using an inhaler, NRT was seen as helping with
behavioural aspects of stopping smoking by, for example,
giving smokers something to do with their hands and
something to focus on generally.
'I think for a lot of patients you're breaking the habit, so you're
not just treating their nicotine withdrawal, so if you're using
nicotine replacement, giving them an inhalator might help
them reduce the habit of having to have something to do with
their hands (GP 19)'.
NRT was also perceived as offering psychological help by
clearly marking the beginning of a cessation attempt and
giving it more importance.
'Nicotine replacement is often a step in their lives, a threshold
that they are definitely doing it, rather than just having a day
off, two days off, and then going back to it (GP 8)'.
In GPs' views, NRT also provided smokers with a sense of
hope, which was considered as possibly the sole reason
why NRT had an impact on quit rates. That NRT might
work entirely on the basis of a placebo rather then having
an active effective component was however not necessar-
ily seen negatively.
'I think a lot of patients that I give it to do find it's given them
a lot of benefit. Personally, I think it's largely in the mind; I
wonder, but if it's a panacea then fine as well (GP 18)'.
Based on the belief that it helped smokers to stop smok-
ing, NRT was mostly seen as effective enough to justify its
cost. It would prevent future smoking-related illnesses
and as a result reduce future health care costs. In addition,
the cost of NRT was considered small, which was helped
through its use being confined to a brief period.
Even though GPs were generally positive about NRT, a
theme emerged that NRT was perceived as largely ineffec-
tive unless smokers also received behavioural support for
smoking cessation. When describing sources of such
behavioural support GPs were making reference to nurses
working at the practice or smokers' clinics operated by the
primary care trust. Contributing to this sense of depend-
ence on behavioural support was a concern that smokers
would simply relapse without addressing psychological
aspects of smoking, such as reasons why patients smoked,
when they smoked, and why they wanted to give up.
Another concern was that smokers would transfer their
nicotine dependence from smoking to using NRT unless
they received support and guidance on how to use it, and
how they should cease using it over time. There was also a
sense that smokers who did not want to use behavioural
support in addition to NRT were not entirely committed
to stopping smoking and were therefore less likely to stop
smoking.
'It's a help, but I wouldn't say it's the total therapy. I think these
people need a bit of counselling, they need to change their life-BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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styles. ... So yes, you know, in a certain way nicotine does help,
but there needs to be an adjuvant therapy added to it (GP 9)'.
As a result of this perceived lack of effectiveness in the
absence of behavioural support, some GPs said they
would only prescribe NRT for smokers who accepted
some form of behavioural support, either on a one-to-one
or a group basis.
'We've got the nurse running a cessation clinic and we don't
prescribe any of those products unless they make a commitment
to come along to that (GP 13)'.
The risks associated with NRT were seen as negligible,
even though some negative impacts on the cardiovascular
system and concerns about the abuse potential of NRT
were mentioned.
'Nicotine replacement therapy is completely safe (GP 2)'.
Bupropion
The key theme that emerged about bupropion was GPs'
concerns about its side-effects. Concerns were mostly
related to epileptic convulsions and death. Awareness of
these side-effects came from media reports and experi-
ences with patients. It was acknowledged however that
deaths were rare. As a result of the concerns about the
side-effects, GPs were reluctant to prescribe bupropion
and perceived it only as a second-line treatment after NRT.
'I tend to say nicotine replacement first before Zyban, I don't
quite know why. ... I think that might be my own sort of preju-
dice about Zyban because it's had some bad press. ... I think
there has been some deaths, hasn't there, with Zyban. So I
think that's probably why I'm a bit more cautious with it. Sec-
ond line Zyban, I think, even though I know it shouldn't be, but
I think that's because of my preconceived ideas that I've got
about it, that it is potentially dangerous, isn't it, even though
the numbers are miniscule (GP 7)'.
Some therefore only prescribed it for smokers who had
unsuccessfully used NRT to stop smoking. GPs also tried
to limit the number of smokers that would use bupropion
by not offering it to their patients, but instead waiting for
smokers to request it. Some also actively discouraged
smokers from using bupropion.
'If you come to see me and say that, "I would really like to stop
smoking", I don't go here's some Zyban. I will sort of discuss the
different options and alternatives and I might mention Zyban
but I usually actually leave it up to the patient to say, "Oh I've
heard there's something called Zyban can you tell me a bit
about that". And I have to be pushed quite hard to prescribe
Zyban (GP 2)'.
Some had stopped prescribing it altogether.
'I've stopped prescribing it completely since its negative publicity
came out because of the side-effects that were recorded (GP 6)'.
In spite of concerns about the side-effects, it was acknowl-
edged that bupropion could help smokers to stop smok-
ing. It was mentioned that bupropion would reduce the
cravings for cigarettes and that it was particularly helpful
for heavy smokers. Akin to perceptions about the effec-
tiveness of NRT, GPs recognised that many smokers
would still fail even if they used bupropion. Low compli-
ance due to side-effects was seen as limiting the effective-
ness of bupropion, attributed to smokers discontinuing
the treatment.
'Half of the patients have successfully quit the smoking and they
swear by that it has reduced their craving and things like that
and they have been helped to stop the smoking. There's a quar-
ter of the patients who had side effects like sleeplessness etc, and
had to give up. The other quarter probably haven't been really
successful because the craving is still strong (GP 12)'.
Based on the belief that it helped smokers to stop smok-
ing, bupropion was mostly seen as being effective enough
to justify its cost. It would prevent smoking-related mor-
bidity leading to substantial cost-savings. This view was
supported by the perception that bupropion was helpful
for heavy smokers who were also most likely to incur large
health-care costs in the future. The positive perception of
cost-effectiveness was further supported by the recogni-
tion that bupropion was only used for a short period and
that the monetary cost for this treatment period was quite
small.
'I'm not really sure how expensive it is but you only give it for 2
months so it can't be that expensive and again I think if it cre-
ates one long-term non-smoker then it probably paid for the
other 99 people that you've given 2 months worth and then
chucked it in the bin (GP 2)'.
Some, however, also regarded bupropion as relatively
expensive, at least in relation to NRT.
Summary of results (Study 1)
Study 1 shows that GPs are broadly positive about NRT,
but believe that it is largely ineffective if offered without
behavioural support. Underlying this perception of inef-
fectiveness of NRT if used without additional support
were the perceptions that the use of NRT without behav-
ioural support would neglect the psychological aspects of
smoking and that it would be misused. In addition,
bupropion was seen as having too many side-effects to be
used as a first line treatment.BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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Study 2
Prevalence of beliefs and intentions
Whereas around 79% of GPs agreed that NRT was effec-
tive, only 27% agreed that NRT was effective if used with-
out behavioural support for smoking cessation (Table 3).
Furthermore, just 64% agreed that bupropion was effec-
tive. While 64% agreed that NRT was cost-effective, fewer
than 50% agreed that bupropion was cost-effective. More
than 66% expressed concern about the side-effects of
bupropion and 21% believed bupropion was dangerous.
Reflecting these beliefs, most GPs intended to prescribe
NRT to all motivated smokers, although only a minority
intended to prescribe NRT without support, or bupro-
pion.
Path analysis for intentions to prescribe NRT
'Perceived effectiveness' and 'perceived cost-effectiveness'
had direct effects on 'intentions to prescribe NRT' (Table
4, Figure 1). 'Perceived effectiveness' also had a direct
effect on 'perceived cost-effectiveness'. 'Perceived effec-
tiveness' had an indirect effect on 'intentions to prescribe
NRT' operating through 'perceived cost-effectiveness'.
Adding up the direct and indirect effects, 'perceived effec-
tiveness' (B = .48) had the largest total effect on 'inten-
tions to prescribe NRT', followed by 'perceived cost-
effectiveness' (B = .18).
Path analysis for intentions to prescribe NRT without support
'Perceived ineffectiveness' and 'perceived neglect of psy-
chological aspects of smoking' had direct effects on 'inten-
tions to prescribe NRT without behavioural support'
(Table 5, Figure 2). 'Perceived incorrect use' and 'perceived
neglect of psychological aspects of smoking' had direct
effects on 'perceived ineffectiveness'. 'Perceived incorrect
use' and 'perceived neglect of psychological aspects of
smoking' had indirect effects on 'intentions to prescribe
NRT without support' operating through 'perceived inef-
fectiveness'. Adding up the direct and indirect effects, 'per-
ceived neglect of psychological aspects of smoking' (B = -
.56) had the largest total effect on intentions to prescribe
NRT without support, followed by 'NRT without support
is ineffective' (B = -.33) and 'NRT without support will be
used incorrectly' (B = -.19).
Path analysis for intentions to prescribe bupropion
'Perceived effectiveness', 'perceived cost-effectiveness',
'concerns about side-effects', and 'perceived danger' had
direct effects on 'intentions to prescribe bupropion' (Table
6, Figure 3). 'Perceived effectiveness' also had a direct
effect on 'perceived cost-effectiveness' and 'perceived dan-
ger' also had a direct effect on 'concerns about side-
effects'. 'Perceived effectiveness' had an indirect effect on
'intentions to prescribe bupropion' operating through
'perceived cost-effectiveness'. 'Perceived danger' had an
indirect effect on 'intentions to prescribe bupropion'
operating through 'concerns about side-effects'. Adding
up the direct and indirect effects, 'perceived effectiveness'
(B = .32) had the largest total effect on 'intentions to pre-
scribe bupropion', followed by the perceptions that 'per-
ceived danger' (B = -.31), 'concerns about side-effects' (B
= -.30), and 'perceived cost-effectiveness' (B = .22).
Summary of results (Study 2)
Study 2 showed that while the majority of GPs perceived
smoking cessation medications as effective, a sizable pro-
portion did not. In addition, only a minority believed that
NRT without additional support for smokers was effective.
GPs were divided about whether NHS smoking cessation
medications were cost effective. Path analysis suggested
that these beliefs were strongly related to GPs' intentions
to prescribe smoking cessation medications. Many GPs
associated serious side-effects with bupropion which was
negatively associated with GPs intentions to prescribe
bupropion.
Table 3: Prevalence of beliefs and intentions
Proportion
Beliefs (mean, SD) Agree (> 4) Neutral (4) Disagree (< 4) Missing
NRT is effective. (5.23, 1.27) 79.4% (291) 11.7% (43) 8.9% (33) -
NRT without behavioural support is effective. a (4.59, 1.55) 26.5% (96) 20.7% (76) 52.5% (190) 1.4% (5)
NRT is cost-effective. (4.86, 1.52) 64.1% (234) 20.0% (73) 15.8% (58) 0.5% (2)
Bupropion is effective. (5.04, 1.44) 65.4% (240) 14.2% (52) 20.4% (75) -
Bupropion is cost-effective. (4.52,1.59) 45.9% (166) 24.9% (90) 29.3% (106) 1.4% (5)
Concerned about so-effects of bupropion. (3.86, 1.60) 66.2% (242) 18.3% (67) 15.5% (57) 0.3% (1)
Bupropion is dangerous. (5.00, 1.44) 20.7% (76) 13.6% (50) 65.7% (241) -
Intentions (mean, SD) Intend (> 4) Neutral (4) Do not intend (< 4) Missing
Intention to prescribe NRT. (5.34, 1.55) 79.8% (293) 4.9% (18) 15.3% (56) -
Intention to prescribe NRT without support. (3.14, 1.84) 29.5% (108) 9.8% (36) 60.7% (222) 0.3% (1)
Intention to prescribe bupropion. (4.85, 2.01) 20.7% (76) 9.5% (35) 69.8% (256) -
Notes: a reversed scale.BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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Discussion
Beliefs about effectiveness
The proportion of GPs that perceived NRT as ineffective in
the current study confirms findings of previous studies
conducted among English and Welsh GPs [9,20]. To date,
the prevalence of beliefs about the effectiveness of bupro-
pion and NRT without support have not been estimated.
GPs in Study 1 and more than 50% of GPs in Study 2 per-
ceived NRT without support as ineffective. These beliefs
appear at odds with meta-analyses which show that NRT
is effective independent of the intensity of additional sup-
port [5]. Whilst NRT is effective on its own, combining it
with behavioural support is believed to lead to a higher
quit rates than each on its own [2-4], although good evi-
dence for this is lacking.
The results from both our quantitative and qualitative
research suggested that two beliefs underlie the belief that
NRT was ineffective without behavioural support. The
first is that without behavioural support smokers will fail
to address the psychological aspects of smoking (e.g. that
smokers do not plan in advance how to deal with crav-
ings). The second belief is that NRT without behavioural
support will be used incorrectly (e.g. smokers may use it
in addition to smoking). These two beliefs may be impor-
tant targets for interventions aimed at changing GPs'
beliefs about the effectiveness of NRT without support.
Interventions may also need to address how smokers are
educated about using NRT. It was expected that the effect
of perceptions about neglecting psychological aspects of
smoking when NRT is used without behavioural support,
on intentions to prescribe NRT without support, would
operate entirely through beliefs about the effectiveness of
NRT if used without support in Study 2. The remaining
direct effect may be related to the way in which GPs con-
ceptualised the effectiveness of NRT without support.
The results of Study 1 suggested that GPs were reluctant to
prescribe NRT without behavioural support because they
believed that it is largely ineffective without it. Study 2
confirmed these findings showing that the more GPs
believed that NRT without support was ineffective the less
likely they were to prescribe it. Other studies have also
found that GPs believed that NRT should not be pre-
scribed if smokers do not want additional support [34].
However, we believe that the current study is the first to
highlight the importance of perceived effectiveness as an
explanation for GPs' reluctance to prescribe NRT without
behavioural support. In contrast, the NICE Public Health
Guideline and the recent White Paper are clear in that
smokers should be offered a prescription for NRT regard-
less of whether or not they also want intensive behav-
ioural support for smoking cessation [1,7]. Study 2 also
showed that the more GPs believed that NRT and bupro-
pion were ineffective, the less likely they were to report
prescribing them.
A question that arises, though, is how GPs interpret effec-
tiveness. They may interpret it (i) with reference to
whether smokers are helped at all, or (ii) with reference to
the clinical impact provided (e.g. low Number Needed to
NRT path model; unstandardised coefficients, M = mean, SD  = standard deviation Figure 1
NRT path model; unstandardised coefficients, M = mean, SD 
= standard deviation.
Intentions to prescribe
NRT
(M: 5.34, SD: 1.55)
Perceived effectiveness
(M: 5.23, SD: 1.27)
Perceived cost-effectiveness
(M: 4.86, SD: 1.52)
.18
.36
.68
 
Table 4: NRT: direct, indirect, and total effects on beliefs and intentions
Outcome variable Predictor variable Effects a
Direct Indirect Total
Intention to prescribe NRT 
SMC = 0.19, 95% CI: .12 to .27, p < .01.
f2 = 0.23
Perceived effectiveness .36*** .12*** .48***
Perceived cost-effectiveness .18 *** - .18***
Perceived cost-effectiveness 
SMC = 0.33, 95% CI: .23 to .43, p < .01.
Perceived effectiveness .68*** - .68***
Notes: a unstandardised coefficients, **p < 0.05, ***p < 0.01.BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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Treat (NNT) [35]). Whilst a negative response to the
former can be interpreted as caused by lack of knowledge
or rejection of the evidence, the latter interpretation may
reflect GPs' evaluations of the perceived clinical impact
informed either by personal experience, the published evi-
dence or both. Given the large proportion of smokers that
will fail to stop despite using the most effective treat-
ments, such an assessment of clinical impact could be
considered accurate. Future research needs to address how
GPs conceptualise effectiveness. Combined treatments
(including behavioural support and nicotine dependence
medications) have produced a NNT of 50 to save one life-
year [36]. This compares favourably with other medical
interventions. However, even if GPs' beliefs could be seen
as accurate, beliefs that smoking cessation medications
are ineffective should arguably not interfere with smokers'
chances of being offered them.
Beliefs about cost-effectiveness
Sixty-four percent of GPs believed that NRT was cost-effec-
tive. In 2001, only 47% reported that they believed NRT
was cost-effective [9]. However, fewer than half of GPs
believed that bupropion was cost-effective. Beliefs about
cost-effectiveness had a direct effect on intentions to pre-
scribe NRT and bupropion. These findings, illustrating the
importance of beliefs about the cost-effectiveness, build
upon the findings from a recent study showing that GPs
who believed that NRT or bupropion were effective
enough to make the NHS pay for them also believed that
NRT and bupropion should be available on prescription
[11]. The current study is the first to show the importance
of GPs' beliefs about cost-effectiveness with regards to
GPs' motivation to make smoking cessation medications
available for smokers. Interestingly, in Study 1, GPs talked
about cost-effectiveness in terms of cost-savings, rather
than cost-per-life-year (quality-adjusted) saved, as prac-
ticed by institutions [4]. It appears therefore that GPs
awareness of how cost-effectiveness judgments are made
uses a different framework to that used by policymakers.
In summary, GPs appear to consider cost in relation to
effectiveness, in keeping with the recommendation that
they do so by agencies such as the National Institute for
Clinical Excellence (NICE) [22]. Unfortunately, however,
GPs' judgments do not match the accepted evidence, with
many judging some of the most cost-effective of all health
care interventions, that is, smoking cessation medications,
as not cost-effective.
Concerns about the side-effects of bupropion
GPs in Study 1 perceived that the adverse effects of bupro-
pion were too great to justify its use as a routine nicotine
dependence treatment. These findings are in accord with
the results of a recent cross-sectional survey which found
that GPs' concerns about the side-effects of bupropion
were correlated to GPs' not fulfilling prescription requests
for bupropion [11]. The quantitative study provides addi-
tional support by being the first to show a link between
NRT without support path model; unstandardised coeffi- cients, M = mean, SD = standard deviation Figure 2
NRT without support path model; unstandardised coeffi-
cients, M = mean, SD = standard deviation.
Intentions to prescribe NRT
without support
(M: 3.14, SD: 1.84)
Perceived ineffectiveness
(M: 4.59, SD: 1.55)
Perceived neglect of
psychological aspects of smoking
(M: 5.24, SD: 1.39)
Perceived incorrect use
(M: 4.38, SD: 1.53)
.57
.33
.19
.50
 
Table 5: NRT without support: direct, indirect, and total effects on beliefs and intentions
Outcome variable Predictor variable Effects a
Direct Indirect Total
Intention to prescribe NRT without support
SMC = 0.31, 95% CI: .23 to .39, p < .01. f2 = 0.45
Perceived ineffectiveness (without support) -.33*** - -.33***
Perceived neglect of psychological aspects of smoking -.50*** -.06*** -.56***
Perceived incorrect use - -.19*** -.19***
Perceived ineffectiveness (without support) Perceived incorrect use .57*** - .57***
SMC = 0.43, 95% CI: .36 to .52, p < .01. Perceived neglect of psychological aspects of smoking .19*** - .19***
Notes: a unstandardised coefficients, **p < 0.05, ***p < 0.01.BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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anticipated side-effects, perceptions of danger and
reduced motivation to prescribe bupropion. This suggests
that there may be a causal influence of concerns about
side-effects leading to GPs being less likely to offer bupro-
pion, as previously suggested [11].
In Study 2 a similar proportion of GPs (66%) to that
reported in a previous study using a random sample of UK
GPs (69%) [11] were concerned about the side-effects of
bupropion. One in five GPs believed that bupropion is
dangerous. In the UK there has been a considerable
amount of negative media response to the safety of bupro-
pion prompting a response from the Medicines Control
Agency (MCA) to highlight the relative safety of bupro-
pion [37]. Recent figures show that prescriptions for
bupropion in the UK have fallen dramatically to approxi-
mately one-third of the level in 2000/01 [38]. This may
reflect the negative media reports and the consequent
reluctance of GPs to prescribe bupropion. The Royal Col-
lege of Physicians considers the risk of seizures to be small
and no more than that incurred by the use of other anti-
depressants [39]. Some GPs may be strongly influenced
by short-term harms as opposed to the long-term benefit
of stopping smoking regardless of their likelihoods. Sei-
zures, one of the most severe side-effects, occur in less
than 0.1% of users [4], whilst one in every two smokers
will die prematurely if they continue to smoke [39].
Whether it is possible or advisable to alter GPs beliefs is a
question of debate.
Strengths and limitations
Study 1
A strength of this study is that the qualitative method
revealed previously not recorded beliefs and behavioural
patterns. The study has two limitations. First, financial
and time constraints limited the length of the interviews.
This limited the depth with which beliefs could be
explored. Second, the sample of the current study was
restricted to GPs working in MRC GPRF-registered prac-
tices. Although MRC GPRF practices are representative in
terms of the distribution of partnership size compared to
the distribution of practices in the UK, these practices vol-
unteer to dedicate some of their efforts to enhancing evi-
dence-based medicine. GPs working in such practices and
those that participated in the current study are thus likely
to have a more favourable view of evidence-based medi-
cine than GPs working in practices that do not. The find-
ings may therefore reflect a more favourable perspective
on smoking cessation medications and services than may
Bupropion path model; unstandardised coefficients, M =  mean, SD = standard deviation Figure 3
Bupropion path model; unstandardised coefficients, M = 
mean, SD = standard deviation.
Intentions
to prescribe bupropion
(M: 4.85, SD: 2.01)
Perceived effectiveness
(M: 5.04, SD: 1.44)
Perceived cost-effectiveness
(M: 4.52, SD: 1.59)
Concerns about side-effects
(M: 5.00, SD: 1.44)
.61
.22
-.30
.19
Perceived danger
(M: 3.24, SD: 1.36)
-.13 .58
 
Table 6: Bupropion: direct, indirect, and total effects on beliefs and intentions
Outcome variable Predictor variable Effects a
Direct Indirect Total
Intention to prescribe bupropion
SMC = 0.37, 95% CI: .29 to .45, p < .01. f2 = 0.59
Perceived effectiveness .19*** .14*** .32***
Perceived cost-effectiveness .22*** - .22***
Concerns about side-effects -.30*** - -.30***
Perceived danger -.13** -17*** -.31**
Perceived cost-effectiveness
SMC = 0.33, 95% CI: .22 to .44, p < .01.
Perceived effectiveness .61*** - .61***
Concerns about side-effects
SMC = 0.30, 95% CI: .22 to .38, p < .01.
Perceived danger .58*** - .58***
Notes: a unstandardised coefficients, **p < 0.05, ***p < 0.01.BMC Public Health 2006, 6:277 http://www.biomedcentral.com/1471-2458/6/277
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have been found in a more representative sample of UK
GPs. In addition, only a small proportion of GPs from
GPRF practices volunteered to participate, possibly mak-
ing the sample unrepresentative of GPRF practices on the
whole. Those who volunteered may have been more
favourable towards smoking cessation medications and
services than those GPs who did not.
Study 2
The predictive ability of the models used to explain inten-
tions to recommend smoking cessation services compares
very favourably to the effects sizes achieved in predicting
intentions that are generally reported with motivational
theories (e.g. Theory of Planned Behaviour) [40]. In addi-
tion, effect sizes in the current study are based upon spe-
cific beliefs instead of more abstract and general concepts
such as the attitudes included in the Theory of Planned
Behaviour. By using specific beliefs the current studies
suggest specific intervention targets to increase GP pre-
scription of smoking cessation medications. There are sev-
eral limitations. Alternative models could have been
constructed from the observed data and these may have
provided different insights. Furthermore, due to financial
limitations only a small number of items could be
included in the survey. This limited (i) the range of beliefs
that could be assessed (e.g. perceived cost, beliefs about
the consequences of behaviour), and (ii) the number of
items used to assess beliefs. The latter prohibited remov-
ing measurement error and thereby decreased the power
of the analysis [40]. Finally, the sample was not randomly
selected from the population of GPs and although the
sample broadly reflected demographic characteristics of
GPs' in the UK, GPs responding via the Internet might not
be representative of the wider population of GPs. GPs
responding via the internet may have different attitudes
towards nicotine dependence medications than the wider
population of GPs. On the current topic, evidence for the
generalisability of results is provided by the observation
that concerns about bupropion matched those of a recent
randomly selected sample of GPs [11].  Furthermore this
method should not affect the relationships between
beliefs and intention to prescribe nicotine dependence
medications. The current sample had a male bias when
compared with the national population of GPs, reflecting
the profile of GPs that are registered with the service pro-
vider. However beliefs and intentions of male and female
GPs did not differ in the current study (analysis not
shown).
Conclusion
The two studies reported here identified substantial reser-
vations amongst GPs about NRT and bupropion. In par-
ticular, these concern the effectiveness of NRT without
additional support, the safety of bupropion and the cost-
effectiveness of NRT and bupropion. Beliefs about the
effectiveness and concerns about safety had large effects
on intentions to prescribe smoking cessation medica-
tions. Path analysis provided clues about beliefs underly-
ing perceptions of ineffectiveness of NRT without
additional behaviour support. Addressing these beliefs
may be important if GPs are to encourage more smokers
to use smoking cessation medications.
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